Henry DH - Reported here are retrospective subset analyses of elderly (>= 65 years old; n = 147), breast (n = 75), and colorectal (n = 42) cancer patients. Results for the primary efficacy endpoint of mean hemoglobin value change from baseline to the end of the study were comparable between dosing groups in all three per-protocol subpopulations (range, 1.4-2.2 g/dL). Rates of adverse events and clinically relevant thrombotic vascular events (range, 0%-9%) were comparable between dosing groups in all three subpopulations. Generally, dose withholds and reductions were less common in the Q2W dosing group. In all three subpopulations, >= 80% of patients were maintained on the Q2W dosing regimen throughout the study. Based on findings from the overall prospective study as well as these three retrospective subset analyses, 80,000 U of epoetin alfa Q2W provides comparable efficacy and safety as 40,000 U of epoetin alfa once weekly, making it a viable treatment option for chemotherapy-induced anemia.
See all
